BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
Rhea-AI Summary
BiomX (NYSE American: PHGE), a clinical-stage company focused on developing phage therapies targeting specific pathogenic bacteria, has scheduled its second quarter 2025 financial results and program updates announcement for August 13, 2025, before U.S. markets open.
The company will host a conference call and audio webcast at 8:00 AM ET on the same day. Participants are advised to register at least 5 minutes before the call begins. Those not planning to ask questions are encouraged to join via the webcast, which will be available both live and archived in the Investors section of BiomX's website.
Positive
- None.
Negative
- None.
News Market Reaction – PHGE
On the day this news was published, PHGE gained 49.43%, reflecting a significant positive market reaction. Argus tracked a peak move of +8.9% during that session. Argus tracked a trough of -31.4% from its starting point during tracking. Our momentum scanner triggered 62 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $19M at that time. Trading volume was exceptionally heavy at 54.5x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
NESS ZIONA, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will report its second quarter 2025 financial results and program updates before the open of the U.S. financial markets on Wednesday, August 13, 2025. The Company will host a conference call and a live audio webcast at 8 a.m. ET, to discuss the second quarter of 2025 financial results and provide program updates.
To ensure you are connected prior to the beginning of the call, BiomX suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, August 13, 2025 |
| Time: | 08:00 AM Eastern Time |
| Conference Call | https://register-conf.media-server.com/register/BI35d84b315cb147c78290b6b8f1fde487 |
| Webcast: | http://edge.media-server.com/mmc/p/89dfoxpe/ |
The live and archived webcast will also be available in the Investors section of the Company’s website at www.biomx.com.
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
BiomX, Inc.
Ben Cohen
benc@biomx.com
FAQ
When will BiomX (PHGE) report Q2 2025 earnings?
What time is BiomX's Q2 2025 earnings call?
How can I access BiomX's Q2 2025 earnings call?
What does BiomX (PHGE) do as a company?
